Atacama Therapeutics, Inc.
PrivateLast Round
Series A
Dec 1, 2023
Total Funding Raised
$2.83M
Company Overview
Atacama Therapeutics, Inc. is a biotechnology company that develops targeted small molecule therapies for dermatological conditions such as Acne Vulgaris and hyperhidrosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Atacama Therapeutics, Inc. Comparables
Compare Atacama Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neuropore Therapies, Inc. | 85% | |
| Vanqua Bio | 84% | |
| PharmatrophiX | 83% |
For institutional investors. Book with your work email.
Atacama Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 1, 2023 |
For institutional investors. Book with your work email.
Atacama Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| KittyHawk Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 1, 2023
$2M round with KittyHawk Ventures and Roy Peterkofsky.
For institutional investors. Book with your work email.
Atacama Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Atacama Therapeutics, Inc.'s valuation, stock price, and market status.
Is Atacama Therapeutics, Inc. a public or private company?
Atacama Therapeutics, Inc. is a private company.
What is the current stock price of Atacama Therapeutics, Inc.?
Atacama Therapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks Atacama Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Atacama Therapeutics, Inc. worth (valuation)?
Valuation information for Atacama Therapeutics, Inc. is not publicly available.
Can I buy Atacama Therapeutics, Inc. stock?
Atacama Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Atacama Therapeutics, Inc.'s last funding round?
Atacama Therapeutics, Inc.'s most recent funding round was Series A on December 1, 2023.
Who are the main investors in Atacama Therapeutics, Inc.?
Key investors in Atacama Therapeutics, Inc. include KittyHawk Ventures.
Will Atacama Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for Atacama Therapeutics, Inc..
How can I track Atacama Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Atacama Therapeutics, Inc.'s shares on secondary markets.